查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1465987

藥品開發和受託製造市場：按服務和最終用戶分類 - 2024 年至 2030 年全球預測

Pharmaceutical Contract Development & Manufacturing Market by Service, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年受託製造市場規模為1,257.3億美元，2024年達到1,362.7億美元，預計2030年將達2,220.4億美元，複合年成長率為8.46%。

受託製造（CDMO）是將藥物開發和製造過程外包給第三方組織。 CDMO 服務涵蓋廣泛的活動，包括藥物發現、配方開發、製程最佳化、放大、監管提交支援以及用於臨床試驗和商業分銷的最終產品製造。透過外包給 CDMO，製藥公司可以專注於其核心競爭力，例如藥物發現和行銷，同時獲得尖端技術和監管專業知識。受託製造的應用涵蓋藥品的整個生命週期。為了降低成本和提高效率而進行製藥外包的趨勢不斷成長，以及需要專業製造能力的生物製藥公司不斷擴大的產品線，正在推動對合約藥物開發和受託製造的需求。此外，隨著製藥業的全球化，對當地生產設施符合監管條件的需求不斷增加，對藥物開發和受託製造服務的需求也不斷增加。然而，與各種國際標準以及複雜的供應鏈管理和物流相關的監管挑戰和合規成本可能會對藥物開發和受託製造市場產生負面影響。然而，個人化醫療和下一代療法的出現正在為合約藥物開發和受託製造機會。此外，隨著受託製造預計將成為對最終用戶有吸引力的選擇。

主要市場統計
基準年[2023] 1257.3億美元
預測年份 [2024] 1362.7億美元
預測年份 [2030] 2220.4億美元
複合年成長率（%） 8.46%

服務終端使用者對生技藥品製造服務的滲透率不斷提高，以遵守嚴格的監管標準

生技藥品製造服務涉及利用活生物體製造複雜的高分子藥物。生技藥品製造包括細胞株開發、上游和下游加工、精製和品質保證。生技藥品原料藥藥製造服務專注於生物來源活性藥物成分（API）的生產。在生技藥品成品製造服務中，供應商專注於成品的配方、填充、精加工和包裝，利用先進技術確保以最高效的方式交付最終的生技藥品治療產品。藥物開發服務描述了一套全面的解決方案，為客戶提供從臨床前階段到商業化的支援。這包括配方開發、分析方法開發、臨床試驗生產、監管提交支援、計劃管理等。藥品製造服務包括藥品的全面製造以及處理各種劑型和輸送系統。藥物原料藥製造涉及活性藥物成分的合成和生產，活性藥物成分是所有藥品的重要組成部分。膠囊製造服務專門生產膠囊劑型。該服務包括封裝過程和任何必要的塗層或印刷。口服液體藥物製造服務涉及口服液體藥物的配方和製造。腸外/注射製造服務專注於製造用於注射或輸注到體內的無菌藥物。錠劑製造服務通常涵蓋含有原料藥和各種賦形劑的壓縮固態劑型的生產。藥物最終劑型製造包括實現藥物產品最終消耗型態（例如固態、半固態、液體或其他專門劑型）所需的所有步驟。二次包裝服務包括附加包裝，可傳達必要的資訊、提供保護並確保初級包裝藥品的完整性。

最終用戶：大型製藥公司廣泛採用製藥 CDMO 服務來管理複雜的藥物開發。

大型製藥公司經常從事合約開發和製造，以管理大量藥品生產的複雜性，並利用內部不具備的專業技術和能力。大型製藥公司更喜歡先進的製造技術、服務多元化市場的全球監管專業知識以及用於大量生產的可靠的可擴展性。學名藥公司主要專注於生產和銷售專利到期藥物。非專利藥公司在成本和效率方面競爭激烈，青睞能夠以較低成本提供高品質產品的契約製造。學名藥公司以具有成本效益的生產能力、快速的交貨時間和強大的品管系統為中心，以確保符合生物等效性的監管標準。中小型製藥公司通常以創新和敏捷性為特點，但它們通常缺乏大型製藥公司廣泛的基礎設施。中小型藥廠更青睞靈活敏捷、能夠適應小規模生產和中試批次的CDMO服務。中小型製藥公司與 CDMO 合作，提供針對利基市場和治療的個人化和專業服務。

區域洞察

在醫療支出不斷成長和政府支持政策的推動下，亞太地區是受託製造廠商(CDMO) 快速成長的市場。亞太新興經濟體正在大力投資生物技術，並以其學名藥製造能力而聞名。中國的「中國製造2025」計畫和印度政府發展國內醫藥產業的努力正在影響亞太地區的CDMO活動。美洲地區是一個成熟的醫藥 CDMO 市場，其特點是醫療服務支出高、研發活動廣泛、生物技術和製藥公司眾多。美洲消費者需要高品質的產品並優先考慮法規遵循。因此，CDMO 正在投資先進的製造技術和能力，以滿足這些市場需求。歐盟 (EU) 是高品質藥品製造和創新的重要中心。對品質和遵守品管生產規範 (GMP) 的重視正在增加人們獲得各種先進藥物的機會。歐洲、中東和非洲地區最近的專利主要集中在藥物配方和先進的輸送系統。中東和非洲部分地區是新興市場，醫療基礎設施投資增加，藥品需求不斷成長。

FPNV定位矩陣

FPNV定位矩陣對於評估藥物開發和受託製造市場極為重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限。最前線 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對藥物開發和受託製造市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該細分市場競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、碎片化主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：包括新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：包括對未來技術、研發活動和突破性產品開發的智力見解。

本報告解決了以下關鍵問題：

1.藥物開發和受託製造市場的市場規模和預測是多少？

2.在藥物開發和受託製造市場的預測期內，我們應該考慮投資哪些產品和應用？

3.藥物開發和受託製造市場的技術趨勢和法規結構是什麼？

4.藥物開發和受託製造市場主要供應商的市場佔有率是多少？

5.進入藥物開發/受託製造市場的適當型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對學名藥和生物療法的需求增加
      • 加大醫藥研發投入
      • CDMO數量增加以及CDMO加大對先進製造技術的投資
    • 抑制因素
      • 採用序列化
    • 機會
      • 對核子醫學和專科藥物的日益關注
      • 對細胞和基因治療的需求不斷成長
    • 任務
      • 國家間貿易政策的多樣性
  • 市場區隔分析
    • 服務：最終用戶更多普及生物製藥製造服務，以遵守嚴格的監管標準
    • 最終用戶：大型製藥公司廣泛採用製藥 CDMO 服務來管理複雜的藥物開發。
  • 市場趨勢分析
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析
  • 客戶客製化
    • 擴建亞洲國家CDMO製造地
    • CDMO產業整合
    • 增加對新興市場的臨床試驗外包

第6章 藥品開發與受託製造市場：依服務分類

  • 介紹
  • 生物製藥製造服務
  • 藥物開發服務
  • 藥品製造服務
  • 二次包裝服務

第7章 藥物開發與受託製造市場：依最終使用者分類

  • 介紹
  • 大型製藥公司
  • 非專利藥公司
  • 中小型製藥公司

第8章北美和南美的藥品開發和受託製造市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太藥物開發與受託製造市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲的藥品開發和受託製造市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析

第12章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-4316E4E8930E

[187 Pages Report] The Pharmaceutical Contract Development & Manufacturing Market size was estimated at USD 125.73 billion in 2023 and expected to reach USD 136.27 billion in 2024, at a CAGR 8.46% to reach USD 222.04 billion by 2030.

Pharmaceutical contract development and manufacturing (CDMO) refers to outsourcing drug development and manufacturing processes to third-party organizations. CDMO services cover a broad range of activities, including drug discovery, formulation development, process optimization, scale-up, regulatory submission support, and the eventual manufacturing of the final product for clinical trials or commercial distribution. Pharmaceutical companies can concentrate on their core competencies, such as drug discovery and marketing, by outsourcing to CDMOs while gaining access to cutting-edge technologies and regulatory expertise. The applications for contract development and manufacturing span the entire lifecycle of pharmaceutical products. The increasing trend of pharmaceutical outsourcing due to cost reduction and efficiency gains and expanding pipelines of biopharmaceutical companies requiring specialized manufacturing capabilities have increased the demand for pharmaceutical contract development and manufacturing. In addition, the globalization of the pharmaceutical industry drives the need for local manufacturing facilities to navigate regulatory landscapes, developing a growing need for pharmaceutical contract development and manufacturing services. However, regulatory challenges and compliance costs associated with varying international standards and complexities in supply chain management and logistics can negatively affect the pharmaceutical contract development and manufacturing market. Nevertheless, the emergence of personalized medicine and next-generation therapies creates opportunities for pharmaceutical contract development and manufacturing. Moreover, investments by vendors in advanced manufacturing technologies such as continuous manufacturing and single-use systems are expected to make pharmaceutical contract development and manufacturing an attractive option for end-users.

KEY MARKET STATISTICS
Base Year [2023] USD 125.73 billion
Estimated Year [2024] USD 136.27 billion
Forecast Year [2030] USD 222.04 billion
CAGR (%) 8.46%

Service: Rising penetration of biologics manufacturing services by end-users to adhere to stringent regulatory standards

Biologics manufacturing services encompass the production of complex large-molecule drugs from living organisms. Biologics manufacturing includes cell line development, upstream and downstream processing, purification, and quality assurance. The biologics API manufacturing services focus on producing active pharmaceutical ingredients (APIs) derived from biological sources. In biologics finished dosage forms manufacturing services, vendors specialize in the formulation, fill, finish, and packaging of final products, leveraging advanced aseptic processing techniques to ensure that the final biologic therapeutic products are delivered in their most productive form. Drug development services provide a comprehensive suite of solutions to support clients from preclinical stages to commercialization. This includes formulation development, analytical method development, clinical trial manufacturing, regulatory submission support, and project management. Pharmaceutical manufacturing services include the full-scale production of medications and the handling of various dosage forms and delivery systems. Pharmaceutical API manufacturing involves synthesizing and producing active pharmaceutical ingredients that are the crucial components of any medication. Capsule manufacturing services specialize in the production of capsule dosage forms. The service covers the encapsulation process and any necessary coating or printing. Oral liquid manufacturing services pertain to formulating and producing liquid drugs designed for oral administration. Parenteral/injectable manufacturing services focus on making sterile medications for injection or infusion into the body. Tablet manufacturing services cover creating compacted solid dosage forms that typically contain an API with various excipients. Pharmaceutical finished dosage form manufacturing encompasses the full spectrum of processes required to complete the final, consumable form of medications, whether solid, semi-solid, liquid, or other specialized forms. Secondary packaging services involve the additional packaging that conveys necessary information, provides protection, and ensures the integrity of the primary packaged pharmaceutical products.

End User: Big pharma companies widely adopting pharmaceutical CDMO services to manage complex drug development

Large pharmaceutical companies often engage in contract development and manufacturing to manage the complexity of producing large quantities of drugs and to tap into specialized technologies or capacities not available in-house. Big pharma companies prefer advanced manufacturing technology, global regulatory expertise for diverse markets, and reliable scalability for high-volume production. Generic pharmaceutical companies primarily focus on the production and distribution of off-patent drugs. Generic pharmaceutical companies compete heavily on cost and efficiency and prioritize contract manufacturers able to deliver high-quality products with low-cost solutions. Generic pharmaceutical companies are centered on cost-effective production capabilities, fast turnaround times, and a robust quality control system to ensure compliance with regulatory standards for bioequivalence. Small and mid-size pharma companies, often characterized by their innovation and agility, generally lack the extensive infrastructure of their larger counterparts. The preference of small and mid-size pharma companies revolves around flexible and agile CDMO services that can handle smaller-scale productions and pilot batches. Small & mid-size pharma companies collaborate with CDMOs that offer personalized attention and specialized services that cater to niche markets or therapies.

Regional Insights

Asia-Pacific is a rapidly growing market for pharmaceutical contract development and manufacturing organizations (CDMOs) fueled by increasing healthcare expenditure and supportive government policies. The emerging economies in the Asia-Pacific are investing heavily in biotechnology and are known for their generic pharmaceutical manufacturing capabilities. China's "Made in China 2025" plan and India's government aim to advance their domestic pharmaceutical sectors, influencing CDMO activities in the Asia-Pacific. The Americas region is a maturing market for pharmaceutical CDMOs characterized by high spending on health services, extensive R&D activities, and many biotechnology and pharmaceutical companies. Consumers in the Americas expect high-quality products, prioritizing regulatory compliance. This has led CDMOs to invest in advanced manufacturing technologies and capabilities to cater to these market needs. The European Union is a significant hub for high-quality pharmaceutical manufacturing and innovation. A strong emphasis on quality and compliance with Good Manufacturing Practice (GMP) standards has improved access to various advanced drug modalities. Recent patents in the EMEA region are focused on pharmaceutical formulations and advanced delivery systems. The Middle East and parts of Africa are emerging markets with increasing investment in healthcare infrastructure and a growing demand for pharmaceutical products.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pharmaceutical Contract Development & Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pharmaceutical Contract Development & Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pharmaceutical Contract Development & Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Aenova Holding GmbH, Almac Group Limited, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Curia Global, Inc., Danaher Corporation, Delwis Healthcare Pvt. Ltd., Evonik Industries AG, Fabbrica Italiana Sintetici S.p.A., Famar Health Care Services, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Grifols S.A., Jubilant Pharmova Limited, Lonza Group AG, Pfizer Inc., Recipharm AB, Samsung Biologics Co., Ltd., Siegfried AG, The Fareva Group, Thermo Fisher Scientific Inc., Vetter Pharma-Fertigung GmbH & Co. KG, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Pharmaceutical Contract Development & Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Service
    • Biologics Manufacturing Services
      • Biologics API Manufacturing Services
      • Biologics FDF Manufacturing Services
    • Drug Development Services
    • Pharmaceutical Manufacturing Services
      • Pharmaceutical API Manufacturing
        • Capsule Manufacturing Services
        • Oral Liquid Manufacturing Services
        • Parenteral/Injectable Manufacturing Services
        • Tablet Manufacturing Services
      • Pharmaceutical FDF Manufacturing
    • Secondary Packaging Services
  • End User
    • Big Pharma
    • Generic Pharmaceutical Companies
    • Small & Mid-Size Pharma
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Pharmaceutical Contract Development & Manufacturing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pharmaceutical Contract Development & Manufacturing Market?

3. What are the technology trends and regulatory frameworks in the Pharmaceutical Contract Development & Manufacturing Market?

4. What is the market share of the leading vendors in the Pharmaceutical Contract Development & Manufacturing Market?

5. Which modes and strategic moves are suitable for entering the Pharmaceutical Contract Development & Manufacturing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Demand for Generics and Biological Therapies
      • 5.1.1.2. Increasing Investments in Pharmaceutical R&D
      • 5.1.1.3. Increasing Number of CDMOs and Rising Investments in Advanced Manufacturing Technologies by CDMOs
    • 5.1.2. Restraints
      • 5.1.2.1. Introduction of Serialization
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing Focus on Nuclear Medicine and Specialty Drugs
      • 5.1.3.2. Growing need for Cell and Gene Therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Variable Trade Policies Between Countries
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Service: Rising penetration of biologics manufacturing services by end-users to adhere to stringent regulatory standards
    • 5.2.2. End User: Big pharma companies widely adopting pharmaceutical CDMO services to manage complex drug development
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization
    • 5.9.1. Increasing CDMO Manufacturing Footprint in Asian Countries
    • 5.9.2. CDMO Industry Consolidation
    • 5.9.3. Increasing Outsourcing of Clinical Trials to Emerging Markets

6. Pharmaceutical Contract Development & Manufacturing Market, by Service

  • 6.1. Introduction
  • 6.2. Biologics Manufacturing Services
  • 6.3. Drug Development Services
  • 6.4. Pharmaceutical Manufacturing Services
  • 6.5. Secondary Packaging Services

7. Pharmaceutical Contract Development & Manufacturing Market, by End User

  • 7.1. Introduction
  • 7.2. Big Pharma
  • 7.3. Generic Pharmaceutical Companies
  • 7.4. Small & Mid-Size Pharma

8. Americas Pharmaceutical Contract Development & Manufacturing Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Pharmaceutical Contract Development & Manufacturing Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Pharmaceutical Contract Development & Manufacturing Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Alcami Announces Acquisition of West-Coast-Based Pacific Pharmaceutical Services
    • 11.3.2. Piramal Pharma to Invest INR 1,000 Crore for Expansion
    • 11.3.3. eXmoor Pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET DYNAMICS
  • FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS API MANUFACTURING SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS API MANUFACTURING SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS FDF MANUFACTURING SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS FDF MANUFACTURING SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CAPSULE MANUFACTURING SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CAPSULE MANUFACTURING SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY ORAL LIQUID MANUFACTURING SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY ORAL LIQUID MANUFACTURING SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PARENTERAL/INJECTABLE MANUFACTURING SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PARENTERAL/INJECTABLE MANUFACTURING SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TABLET MANUFACTURING SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TABLET MANUFACTURING SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL FDF MANUFACTURING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL FDF MANUFACTURING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIG PHARMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIG PHARMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SMALL & MID-SIZE PHARMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SMALL & MID-SIZE PHARMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 89. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 90. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 124. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 133. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 134. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 143. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 144. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 153. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 154. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 163. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 164. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 173. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 174. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 184. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 193. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 194. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 204. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 213. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 214. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 223. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 224. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 233. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
  • TABLE 234. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM PHARM